Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation

European Journal of Haematology

Volumn 89, Issue 3, 2012, Pages 228-235

  Bleeker, Jonathan S ^a   Gertz, Morie A ^a   Pellikka, Patricia A ^a   Larson, Dirk R ^a   Buadi, Francis ^a   Dingli, David ^a   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Hogan, William ^a   Kumar, Shaji ^a   Rajkumar, S Vincent ^a   Lacy, Martha Q ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Cardiomyopathy; High dose melphalan; Multiple myeloma; Stem cell transplant

Indexed keywords

MELPHALAN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL DECISION MAKING; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; SEPSIS; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; VALVULAR HEART DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART; HUMANS; MALE; MELPHALAN; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 84865125941     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01815.x     Document Type: Article

References (33)

1. Samuels B, Bitran J High-dose intravenous melphalan: a review. J Clin Oncol 1995;13:1786-99.
2. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7.
3. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ, Wilson HE Treatment for multiple myeloma. JAMA 1969;208:1680-5.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
5. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
6. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-7.
7. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-70.
8. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960-3.
9. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-93.
10. Skinner M, Sanchorawala V, Dember LM, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-94.
11. Goldberg M, Antin JH, Guinan EC, Rappeport JM Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-8.
12. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141:758-63.
13. Quezado ZMN, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene FP High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31-6.
14. Olivieri A, Corvatta L, Montanari M, Brunori M, Offidani M, Ferretti GF, Centanni M, Leoni I Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 1998;21:1049-53.
15. Ritchie D, Seymour JF, Roberts AW, Szer J, Grigg AP Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant 2001;28:101-3.
16. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002;99:731-5.
17. 2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010;115:1873-9.
18. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
19. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25.
20. Hosmer D, Lemeshow S Applied Logistic Regressio. New York: John Wiley and Sons Inc., 1989.
21. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-7.
22. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001;19:3350-6.
23. Anderson JR, Cain KC, Gelber RD Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
24. Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers MED, Martin PJ, Friedman DL, Lee SJ Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011;155:21-32.
25. Armenian SH, Sun CL, Shannon T, Mills G, Francisco L, Venkataraman K, Wong FL, Forman SJ, Bhatia S Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011;118:6023-9.
26. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3.
27. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef INM, Tefferi A, Litzow MR Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549-55.
28. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef INM, Porrata LF, Tefferi A, Litzow MR Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025-31.
29. Madan S, Kumar SK, Dispenzieri A, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2011;119:1117-22.
30. Zver S, Zadnik Vesna, Černelč P, Koželj M Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008;88:227-36.
31. Bellavia D, Abraham TP, Pellikka PA, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 2007;20:1194-202.
32. Goodman HJB, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417-25.
33. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998;101:766-9.